Loading...
Canopy Growth faced an 11% revenue decline in Q4 2025 compared to the same period last year, primarily due to weaker international and Storz & Bickel sales. Despite this, the company made progress in reducing operating losses and continues executing on cost-saving strategies.
The company plans to accelerate growth in global medical cannabis, streamline Canadian adult-use operations, and launch new Storz & Bickel products while targeting positive Adjusted EBITDA.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance